Express Pharma

Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC

IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with Tecentriq plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC)

0 473